Amivantamab Plus Lazertinib Vs Osimertinib in First Line, Egfr-Mutant Advanced Nsclc: Patientrelevant Outcomes From Mariposa

Nguyen, D.Besse, B.Cho, B. C.Lee, S. -H.Lee, K. H.Lu, S.Garcia Campelo, M. R.2025-02-252025-02-2520241556-08641556-1380https://hdl.handle.net/20.500.14365/5916eninfo:eu-repo/semantics/closedAccessAmivantamab Plus Lazertinib Vs Osimertinib in First Line, Egfr-Mutant Advanced Nsclc: Patientrelevant Outcomes From MariposaConference Object